Proactiveinvestors recommends
Additional Information
Market: TSX
Sector: Medical
EPIC: ONC
Latest Price: 2.73  (-2.68% Descending)
52-week High: 4.75
52-week Low: 1.70
Market Cap: 230.97M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Oncolytics Biotech
www.oncolyticsbiotech.com
Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company have focused the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth and differentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. The transmission of signals from the cell surface to the cell’s nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the Company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc.
Full Oncolytics Biotech profile here
Pdf

Oncolytics Biotech shares gain after phase 2 lung cancer trial results

13th Sep 2012, 12:50 pm by Deborah Sterescu
Oncolytics' shares gain on news that it meets main goal of first stage phase 2 lung cancer trial, to proceed to next stage Oncolytics' shares gain on news that it meets main goal of first stage phase 2 lung cancer trial, to proceed to next stage

Oncolytics Biotech (TSE:ONC ) (NASDAQ:ONCY) saw its shares rise Thursday after saying it has met the main goal for the first stage of its phase 2 lung cancer trial. 

Shares advanced 6.25 per cent in Toronto to $2.55 this afternoon. 

The company announced today the preliminary results from its US phase 2 trial in patients with squamous cell carcinoma of the lung, using an intravenous dose of Reolysin, together with carboplatin and paclitaxel. 

The primary goal of the two-stage study is to assess the anti-tumor effect of the treatment regimen in terms of objective response rates. 

Up to 19 evaluable patients were to be treated in the first stage. If four or more patients showed a partial response or better, the study would then proceed to the second stage, with up to 55 patients being treated in the entire study. 

This goal was met after 15 patients were enrolled, Oncolytics said, and has therefore decided to proceed to the next stage of the study. Five of the 15 patients showed a partial response, and an additional 8 had stable disease, for a disease control rate of 87 per cent. 

Secondary goals of the trial are to assess progression-free survival and overall survival for the treatment, safety and tolerability, and the number of patients who are free of the disease progression at six months. 

Eligible patients for the study included those with metastatic stage IIIB, or stage IV, or recurrent squamous cell carcinoma of the lung who have never had chemotherapy treatment. 

"These preliminary results are encouraging and further supportive of the decision to conduct a randomized Phase II study examining REOLYSIN in non-small cell lung cancer (NSCLC) patients including those with SCCLC," said president and CEO of the company, Dr. Brad Thompson. 

"Oncolytics Phase II program continues to grow and now includes randomized trials in six separate indications."

The principal investigator of the trial is Dr. Alain Mita of Cedars-Sinai Medical Centre in Los Angeles, California. 

According to the American Cancer Society, in 2012, around 226,160 new cases of lung cancer will be diagnosed. Between 85% and 90% of all lung cancers are classified as non-small cell lung cancer (NSCLC), while squamous cell carcinomas accounts for 25-30% of all lung cancers. 

More people die of lung cancer than from colon, breast, and prostate cancers combined. 

The Calgary-based biotechnology company is focused on the development of oncolytic viruses as potential cancer therapeutics. Its clinical program includes a number of human trials using Reolysin, its formulation of the human reovirus. 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here